A5041685230- Schizophrenia research and treatment
- Health Systems, Economic Evaluations, Quality of Life
- Dementia and Cognitive Impairment Research
- Bipolar Disorder and Treatment
- Treatment of Major Depression
- Pharmaceutical Practices and Patient Outcomes
- Family Caregiving in Mental Illness
- Mental Health and Psychiatry
- Geriatric Care and Nursing Homes
- Alzheimer's disease research and treatments
- Medication Adherence and Compliance
- Adolescent and Pediatric Healthcare
- Healthcare Decision-Making and Restraints
- Health disparities and outcomes
- Cardiac Health and Mental Health
- Chronic Disease Management Strategies
- Migraine and Headache Studies
- Aging, Elder Care, and Social Issues
- Genetic Associations and Epidemiology
- Palliative Care and End-of-Life Issues
- Psychiatric care and mental health services
- Mental Health Research Topics
- Mental Health and Patient Involvement
- Machine Learning in Healthcare
- Explainable Artificial Intelligence (XAI)
Biogen (United States)
2024
Lundbeck (United States)
2016-2023
Deerfield (United States)
2016-2023
Eli Lilly (United States)
2023
Therapeutics Clinical Research
2019
Ibero American University
2019
Lundbeck (Germany)
2018
University of Southern California
2016
Otsuka (United States)
2016
Endo Pharmaceuticals (United States)
2013
To examine medication adherence and discontinuation in two separate groups of patients with schizophrenia or bipolar disorder (BD), who began receiving a long-acting injectable antipsychotic (LAI) versus those changed to different oral monotherapy.The Truven Health Analytics MarketScan Multi-State Medicaid claims database was used identify schizophrenia; Commercial databases were BD. The analyses included adult (≥18 years) either an LAI (no prior therapy) (monotherapy). first day initiating...
Background Agitation is a common neuropsychiatric symptom of Alzheimer disease (AD). Data are scarce regarding agitation prevalence among community‐dwelling patients with AD. Objective To estimate in sample US AD/dementia overall and by severity, using data from electronic health records (EHR). Methods This retrospective database study examined ≥1 EHR record indicating January 2008 to June 2015 no evidence non‐Alzheimer dementia during the 12‐month preindex postindex periods. was identified...
Abstract Background The What Matters Most (WMM) study was initiated to evaluate symptoms, AD-related impacts, treatment-related needs, preferences, and priorities among individuals with or at risk for Alzheimer’s disease (AD) their care partners. objective of this qualitative phase identify a comprehensive set concepts interest that are meaningful across the AD continuum. Methods Interviews were conducted 60 clinically referred partners 5 stages ( n = 12 each): group 1 (non-clinically...
Rationale: Pain is a common problem for patients with chronic obstructive pulmonary disease (COPD). However, pain minimally discussed in COPD management guidelines.Objectives: The objective of this study was to describe prevalence among compared similar other diseases managed care population the southwestern United States (age ≥ 40 yr).Methods: Using data period January 1, 2006 through December 31, 2010, were matched two control subjects without but another illness based on age, sex,...
Few studies have compared adherence between long-acting injectable antipsychotics, especially for newer agents like aripiprazole once-monthly 400 mg (AOM 400; monohydrate) and oral in patients with schizophrenia or bipolar I disorder (BD-I) a real-world setting. Two separate retrospective cohort analyses using Truven MarketScan data from January 1, 2012 to June 30, 2016 were conducted compare medication discontinuation BD-I who initiated treatment AOM vs. changed one antipsychotic...
Although patients with dementia frequently experience neuropsychological symptoms (NPS) such as agitation, which profoundly impacts patients, caregivers, and the healthcare system, few studies have evaluated associated burden of agitation or agitation-related in dementia.This retrospective analysis claims data from Truven Health MarketScan® database (2012-2015) compared clinical characteristics, treatment patterns, resource utilization, costs among behavioral disturbances (BD) versus without...
In this phase of the ongoing What Matters Most study series, designed to evaluate concepts that are meaningful people affected by Alzheimer's disease (AD), we quantified importance symptoms, impacts, and outcomes AD at risk for or with care partners AD.We administered a web-based survey individuals (Group 1: unimpaired cognition evidence pathology; Group 2: factors subjective cognitive complaints/mild impairment; 3: mild AD) moderate 4) severe 5). Respondents rated 42 on scale ranging from 1...
Atypical antipsychotics (AAPs) are often used off-label to manage dementia-associated neuropsychiatric symptoms. In 2005, the US Food and Drug Administration (FDA) issued a boxed warning for use of AAPs in elderly patients. The long-term association this with health outcomes is unknown date.To assess 2005 FDA on psychiatric medication opioid use, events, quality life among individuals dementia.For cross-sectional study, data were analyzed from household component Medical Expenditure Panel...
Insight into the relationship between concepts that matter to people affected by Alzheimer's disease (AD) and clinical outcome assessments (COAs) commonly used in AD studies is limited. Phases 1 2 of What Matters Most (WMM) study series identified quantitatively confirmed 42 treatment-related outcomes are important AD.We compared WMM rated as "very important" or higher items included COAs studies.Twenty designed assess signs, symptoms, impacts across spectrum were selected for review. Among...
This study analyzed hospital readmission rates of patients with schizophrenia who were treated long-acting injectable antipsychotics (LAIs) or oral after being discharged from a hospitalization.Medical claims ages 18-64 and had first hospitalization for serious mental illness (index hospitalization, October 2007 through September 2012) at least one prescription first- second-generation antipsychotic the Truven Health MarketScan Multi-State Medicaid Database. Analyses conducted sole diagnosis...
Objective: Early initiation of antipsychotic treatment in schizophrenia is associated with improved outcomes. This study aimed to determine if long-acting injectable (LAI) early a new episode lower hospitalization rates and healthcare costs real-world setting. Methods: retrospective (January 1, 2007-June 30, 2016) cohort analysis used claims from Truven Health Analytics MarketScan Commercial, Medicaid, Medicare Supplemental databases. In adults ≥18 years schizophrenia, two mutually exclusive...
Alzheimer's disease (AD) is the most common neurodegenerative form of dementia. Pharmacological therapies for symptomatic treatment, such as acetylcholinesterase inhibitors (AChEIs) and memantine, have been available in USA since 2000. Over past decade, few studies analyzed real-world anti-dementia treatment patterns USA. This study evaluated monotherapy AChEIs memantine among newly diagnosed AD patients. A retrospective cohort was conducted using Medicare data Minimum Data Set from 2008 to...
Agitation in individuals with Alzheimer's disease (AD) may predict institutionalization. This study assessed the incremental risk and costs associated agitation AD.A retrospective analysis of National Coordinating Center Uniform Data Set (June 2005-February 2018) was conducted. Incremental institutionalization estimated used number institutionalized AD living by residential setting United States (literature-based), to estimate costs.The included 11,348 AD: 6603 (58.2%) 4745 (41.8%) without...
The objective of this study was to ascertain what extent adults with migraine value an early onset efficacy for preventive treatments.In placebo-controlled clinical trials, treatment eptinezumab resulted in a lower proportion on the first day following infusion (day 1; 14% point-reduction chronic [CM] PROMISE-2 and 8% episodic [EM] PROMISE-1).Adults completed online preference-elicitation thresholding exercise they not having 1 postdosing relative clinically relevant reduction number days...
Treatment of schizophrenia and major depressive disorder (MDD) with atypical antipsychotics (AAPs) show improved efficacy reduced side effect burden compared older antipsychotic medications. However, a risk treatment-emergent adverse events (TEAEs) remains. TEAEs are hard to quantify perspectives on the importance differ across patients between physicians. The current study is qualitative assessment that investigates AAPs from both patient physician provide better understanding occurrence...
Schizophrenia (SCZ) and bipolar disorder (BD) are typically viewed as nonconcurrent psychiatric disorders, yet patients may experience mood SCZ symptoms simultaneously. Several studies have shown overlap between BD susceptibility genes. This study explored the following: (1) patterns of administrative claims; (2) demographic characteristics comorbidities; (3) health care resource use; (4) costs in with diagnoses SCZ, type I (BD-I), both a real-world setting.This was retrospective cohort...
This study explored the association between medication adherence to oral atypical antipsychotics (AAP) and both psychiatric hospitalization associated costs in bipolar I disorder (BD-I) a real-world setting.This retrospective used Truven Health MarketScan Medicaid, Commercial, Medicare Supplemental Claims Databases. Adults were identified if they had BD-I initiated an AAP treatment during identification period (July 1, 2015-June 30, 2016 for July 2015-March 31, Commercial Supplemental)...
Objective: To compare all-cause hospitalization and associated costs among patients with schizophrenia or bipolar disorder (BD) treated long-acting injectable antipsychotics (LAIs).Methods: The Truven MarketScan Medicaid claims database was used to identify schizophrenia; commercial databases were BD. Adult ≥1 LAI claim from January 1, 2013–June 30, 2014 (ID period) identified. first day of initiation the index date; followed for year. Logistic general linear regression models estimate risk...
Few studies have examined patient characteristics and treatment patterns among patients with dementia agitation in the United States (US). To examine real-world of related to who were treated antipsychotics US residential care community-based settings. This retrospective chart review collected physician-level data from 55 90 years old initiated on an antipsychotic medication for January 2018 May 2018. Clinical assessed overall stratified by A total 313 participating physicians, 59.5% whom...
Abstract Introduction This study aims to evaluate the conceptual relevance of four measures disease activity in patients with mild/mild‐moderate Alzheimer's (AD): (1) Disease Assessment Scale–Cognitive Subscale; (2) Cooperative Study–Activities Daily Living Inventory; (3) Neuropsychiatry and (4) Dependence Scale. Methods A model depicting patient experience mild AD was developed via literature review; concepts were compared items measures. Relevance included evaluated by a survey follow‐up...
Major depressive disorder (MDD) is a debilitating psychiatric illness with high cost burden. This analysis evaluates the cost-effectiveness of adjunctive brexpiprazole versus comparator branded treatment for MDD and background antidepressant therapy (ADT) alone from US payer perspective.An economic model was developed to assess ADT on total direct medical costs using 6-week cycle time frame 48 weeks, response remission as primary outcomes. The consisted 3 parts, 1 represent acute phase 2...
Schizophrenia presents a substantial clinical and economic burden to the health-care system. In QUAlity of LIfe with AbiliFY Maintena (QUALIFY), randomized head-to-head study aripiprazole once-monthly 400 mg (AOM 400) compared paliperidone palmitate (PP; 78-234 mg/mo), AOM demonstrated greater improvement in health-related quality life functioning patients stable schizophrenia. The present analysis used health economics assessment data collected during QUALIFY determine direct medical...
The study compared all-cause and major depressive disorder (MDD)-related healthcare resource use (HRU) costs in patients with MDD treated atypical antipsychotic (AAP) adjunctive therapy early or later treatment.Adults antidepressant treatment (ADT) who newly initiated aripiprazole, brexpiprazole, lurasidone, quetiapine between October 1, 2014 September 30, 2015 were identified the IQVIA Real-World Data Adjudicated Claims database; index date was of first AAP claim. Patients stratified into...
There is little evidence regarding the most effective timing of augmentation antidepressants (AD) with antipsychotics (AP) in patients major depressive disorder (MDD) who inadequately respond to first-line AD (inadequate responders). The study's objective was understand association between AP and overall healthcare costs inadequate responders.Using Truven Health MarketScan® Medicaid, Commercial, Medicare Supplemental databases (7/1/09-12/31/16), we identified adult responders if they had one...